Trial Profile
A PHASE 2 RANDOMIZED, DOUBLE-BLIND PLACEBO CONTROLLED TRIAL OF MHAA4549A, A MONOCLONAL ANTIBODY IN COMBINATION WITH OSELTAMIVIR VERSUS OSELTAMIVIR FOR TREATMENT OF SEVERE INFLUENZA A INFECTION
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 13 Jul 2020
Price :
$35
*
At a glance
- Drugs Gedivumab (Primary) ; Oseltamivir
- Indications Influenza A virus infections
- Focus Adverse reactions; Pharmacodynamics; Therapeutic Use
- Acronyms CRANE trial
- Sponsors Genentech; Roche
- 04 Jul 2020 Results published in the Journal of Clinical Pharmacology
- 11 May 2020 Interim results (N=166), published in the Antimicrobial Agents and Chemotherapy
- 16 Mar 2019 Results assessing the Pharmacokinetics of Monoclonal Antibody Mhaa4549a in Patients Hospitalized with Severe Influenza a Infection, presented at the 120th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics